Cypherpunk Technologies Inc.: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 14, 2022 and accepted by EDGAR at Nov 14, 2022, 11:50 ET.
Management's discussion and analysis
As filed, 27,504 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand our results of operations and financial condition. This MD&A is provided as a supplement to, and should be read in conjunction with, our condensed consolidated financial statements and the accompanying notes thereto and other disclosures included in this Quarterly Report on Form 10-Q, including the disclosures under Part II, Item IA “Risk Factors,” and our audited condensed consolidated financial statements and the accompanying notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or the SEC, on March 11, 2022. Our condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and, unless otherwise indicated, amounts are presented in U.S. dollars.
Company Overview
We are a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Our strategy is to identify, acquire, and develop molecules that will rapidly translate into high impact therapeutics that generate durable clinical benefit and enhanced patient outcomes.
Our lead clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. When DKN-01 binds to DKK1, an anti-tumor effect can be generated. DKN-01-based therapies have generated responses and clinical benefit in several patient populations. We are currently studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or colorectal cancer. We entered into an exclusive option and license agreement (the “BeiGene Agreement”) with BeiGene, Ltd., or BeiGene, which granted BeiGene the right to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
Recent Developments
Since June 30, 2022, we have continued to make progress with the development of DKN-01 and our business strategy.
- Presented clinical data from Part A of the DisTinGuish study of DKN-01 plus BeiGene’s tislelizumab in gastroesophageal adenocarcinoma (GEA) cancer patients, and the Phase 2 WAKING study of DKN-01 plus Tecentriq® in oesophagogastric adenocarcinoma (OGA), at the European Society for Medical Oncology (ESMO) Congress
- Presented clinical data from Part B of the DisTinGuish study of DKN-01 plus tislelizumab in GEA cancer patients whose tumors express high levels of DKK1 (DKK1-high), and preclinical data supporting further evaluation of DNK-01 in colorectal cancer (CRC), at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Enrolled first patient into Part C of the DisTinGuish study the randomized controlled trial of DKN-01 plus tislelizumab and chemotherapy in first-line G/GEJ patients
- Enrolled first patient into the Phase 2 DeFianCe study of DKN-01 in second-line CRC patients
Financial Overview
Revenues
Our revenues relate to our performance obligations under the BeiGene Agreement and may include such things as providing intellectual property licenses, performing technology transfer, performing research and development consulting services and notifying the customer of any enhancements to licensed technology or new technology that we discover, among others. We have determined that our performance obligations under the BeiGene Agreement, as evaluated at contract inception, were not distinct and represented a single performance obligation. Upfront payments are amortized to revenue on a straight-line basis over the performance period. Upfront payment contract liabilities resulting from the BeiGene Agreement do not represent a financing component as the payment is not financing the transfer of goods or services, and the technology underlying the license granted reflects research and development expenses already incurred by us. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license revenues. Sales-based milestones and royalties under the BeiGene Agreement will be recognized as royalty revenue in the period the related sale occurred. We generally invoice our licensee upon the completion of the effort or achievement of a milestone, based on the terms of the BeiGene Agreement. Deferred revenue arises from amounts received in advance of the culmination of the earnings process and is recognized as revenue in future periods as performance obligations are satisfied. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.
Research and Development Expenses
Our research and development activities have included conducting nonclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for DKN-01 and TRX518. We recognize research and development expenses as they are incurred. Our research and development expenses consist primarily of:
- salaries and related overhead expenses for personnel in research and development functions, including costs related to stock-based compensation;
- fees paid to consultants and CROs for our nonclinical and clinical trials, and other related clinical trial fees, including but not limited to laboratory work, clinical trial database management, clinical trial material management and statistical compilation and analysis;
- costs related to acquiring and manufacturing clinical trial material; and
- costs related to compliance with regulatory requirements.
We plan to increase our research and development expenses for the foreseeable future as we continue the development of DKN-01 and any other product candidates, subject to the availability of additional funding.
Our direct research and development expenses are tracked on a program-by-program basis and consist primarily of internal and external costs, such as employee costs, including salaries and stock-based compensation, other internal costs, fees paid to consultants, central laboratories, contractors and CROs in connection with our clinical and preclinical trial development activities. We use internal resources to manage our clinical and preclinical trial development activities and perform data analysis for such activities.
We participate, through our subsidiary in Australia, in the Australian government’s research and development (“R&D”) Incentive program, such that a percentage of our eligible research and development expenses are reimbursed by the Australian government as a refundable tax offset and such incentives are reflected as other income.
The table below summarizes our research and development expenses incurred by development program and the R&D Incentive income for the three and nine months ended September 30, 2022 and 2021:
(in thousands)
(in thousands)
| Direct research and development by program: | | Three Months Ended September 30, 2022 | | 2021 | | Nine Months Ended September 30, 2022 | | 2021 |
|---|---|---|---|---|---|---|---|---|
| DKN‑01 program | | $12,080 | | $10,073 | | $33,843 | | $24,060 |
| TRX518 program | | 22 | | 4 | | 88 | | 30 |
| Total research and development expenses | | $12,102 | | $10,077 | | $33,931 | | $24,090 |
| Australian research and development incentives | | $652 | | $1,269 | | $1,276 | | $1,584 |
The successful development of our clinical product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our product candidates or the period, if any, in which material net cash inflows from these product candidates may commence. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:
- the scope, rate of progress and expense of our ongoing, as well as any additional, clinical trials and other research and development activities;
- future clinical trial results; and
- the timing and receipt of any regulatory approvals.
A change in the outcome of any of these variables with respect to the development of a product candidate could result in a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, accounting and audit services.
We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs as well as investor and public relations expenses associated with being a public company.
Interest income
Interest income consists primarily of interest income earned on cash and cash equivalents.
Research and development incentive income
Research and development incentive income includes payments under the R&D Incentive program from the government of Australia. The R&D Incentive program is one of the key elements of the Australian Government’s support for Australia’s innovation system. It was developed to assist businesses in recovering some of the costs of undertaking research and development. The research and development tax incentive provides a tax offset to eligible companies that engage in research and development activities.
Companies engaged in research and development may be eligible for either:
- a 43.5% refundable tax offset for entities with income of less than A$20 million per annum, or
- a 38.5% non-refundable tax offset for all other entities.
We recognize as income the amount we expect to be reimbursed for qualified expenses.
Foreign currency translation adjustment
Foreign currency translation adjustment consists of gains (losses) due to the revaluation of foreign currency transactions attributable to changes in foreign currency exchange rates associated with our Australian subsidiary.
Critical Accounting Policies and Estimates
Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.
Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations— Critical Accounting Policies and Significant Judgments and Estimates” in our Annual Report on Form 10-K filed with the SEC on March 11, 2022 and the notes to the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q. We believe that of our critical accounting policies, the following accounting policies involve the most judgment and complexity:
- revenue recognition;
- accrued research and development expenses;
- research and development incentive receivable; and
- stock-based compensation.
Results of Operations
Comparison of the Three Months Ended September 30, 2022 and 2021
The following table summarizes our results of operations for the three months ended September 30, 2022 and 2021:
(in thousands)
| | | Three Months Ended September 30, 2022 | | 2021 | | Change |
|---|---|---|---|---|---|---|
| License revenue | | $— | | $375 | | $(375) |
| Operating expenses: | | | | | ||
| Research and development | | 12,102 | | 10,077 | | 2,025 |
| General and administrative | | 3,186 | | 2,438 | | 748 |
| Total operating expenses | | 15,288 | | 12,515 | | 2,773 |
| Loss from operations | | (15,288) | | (12,140) | | (3,148) |
| Interest income | | 360 | | 1 | | 359 |
| Interest expense | | (11) | | (9) | | (2) |
| Australian research and development incentives | | 652 | | 1,269 | | (617) |
| Foreign currency loss | | (807) | | (260) | | (547) |
| Net loss | | $(15,094) | | $(11,139) | | $(3,955) |
Revenues
License revenue for the three months ended September 30, 2021 was $0.4 million and relates to the BeiGene Agreement for the development and commercialization of DKN-01 in Asia (excluding Japan), Australia, and New Zealand. No such license revenue was recorded in the three months ended September 30, 2022 as the upfront payment was fully recognized as of December 31, 2021.
Research and Development Expenses
(in thousands)
| Direct research and development by program: | | Three Months Ended September 30, 2022 | | 2021 | | Increase (Decrease) |
|---|---|---|---|---|---|---|
| DKN‑01 program | | $12,080 | | $10,073 | | $2,007 |
| TRX518 program | | 22 | | 4 | | 18 |
| Total research and development expenses | | $12,102 | | $10,077 | | $2,025 |
Research and development expenses were $12.1 million for the three months ended September 30, 2022, compared to $10.1 million for the three months ended September 30, 2021. The increase of $2.0 million in research and development expenses was due to an increase of $1.4 million in clinical trial costs due to patient enrollment and the duration of patients on study, an increase of $0.4 million in payroll and other related expenses due to an increase in headcount of our research and development full-time employees and an increase of $0.2 million in stock based compensation expense due to new stock options and restricted stock units granted to research and development full-time employees.
General and Administrative Expenses
General and administrative expenses were $3.2 million for the three months ended September 30, 2022, compared to $2.4 million for the three months ended September 30, 2021. The increase of $0.8 million in general and administrative expenses was primarily due to an increase of $0.5 million in professional fees due to higher recruiting costs. There was also an increase of $0.2 million in payroll and other related expenses due to an increase in headcount of our general and administrative full-time employees and an increase of $0.1 million in stock based compensation expense due to new stock options and restricted stock units granted to general and administrative full-time employees.
Interest Income
During the three months ended September 30, 2022, we recorded interest income of $0.4 million. During the three months ended September 30, 2021, we recorded an immaterial amount of interest income. The increase of $0.4 million during the three months ended September 30, 2022 as compared to the same period in 2021 was due to higher interest rates.
Australian Research and Development Incentives
We recorded R&D incentive income of $0.7 million and $1.3 million during the three months ended September 30, 2022 and 2021, respectively, based upon the applicable percentage of eligible research and development activities under the Australian Incentive Program, which expenses included the cost of manufacturing clinical trial material.
The R&D incentive receivable has been recorded as “Research and development incentive receivable” in the condensed consolidated balance sheets.
Foreign Currency Gains (loss)
During the three months ended September 30, 2022 and 2021, we recorded foreign currency losses of $0.8 million and $0.3 million, respectively. Foreign currency gains and losses are due to changes in the Australian dollar exchange rate related to activities of the Australian entity.
Comparison of the Nine Months Ended September 30, 2022 and 2021
The following table summarizes our results of operations for the nine months ended September 30, 2022 and 2021:
(in thousands)
| | | Nine Months Ended September 30, 2022 | | 2021 | | Change |
|---|---|---|---|---|---|---|
| License revenue | | $— | | $1,125 | | $(1,125) |
| Operating expenses: | | | | |||
| Research and development | | 33,931 | | 24,090 | | 9,841 |
| General and administrative | | 8,889 | | 7,973 | | 916 |
| Total operating expenses | | 42,820 | | 32,063 | | 10,757 |
| Loss from operations | | (42,820) | | (30,938) | | (11,882) |
| Interest income | | 404 | | 4 | | 400 |
| Interest expense | | (49) | | (39) | | (10) |
| Australian research and development incentives | | 1,276 | | 1,584 | | (308) |
| Foreign currency loss | | (1,305) | | (410) | | (895) |
| Net loss | | $(42,494) | | $(29,799) | | $(12,695) |
Revenues
License revenue for the nine months ended September 30, 2021 was $1.1 million and relates to the BeiGene Agreement for the development and commercialization of DKN-01 in Asia (excluding Japan), Australia, and New Zealand. No such license revenue was recorded in the nine months ended September 30, 2022 as the upfront payment was fully recognized as of December 31, 2021.
Research and Development Expenses
(in thousands)
| Direct research and development by program: | | Nine Months Ended September 30, 2022 | | 2021 | | Increase (Decrease) |
|---|---|---|---|---|---|---|
| DKN-01 program | | $33,843 | | $24,060 | | $9,783 |
| TRX518 program | | 88 | | 30 | | 58 |
| Total research and development expenses | | $33,931 | | $24,090 | | $9,841 |
Research and development expenses were $33.9 million for the nine months ended September 30, 2022, compared to $24.1 million for the nine months ended September 30, 2021. The increase of $9.8 million in research and development expenses was primarily due to an increase of $4.8 million in manufacturing costs related to clinical trial material and manufacturing campaigns and an increase of $3.2 million in clinical trial costs due to patient enrollment and the duration of patients on study. There was also an increase of $1.2 million in payroll and other related expenses due to an increase in headcount of our research and development full-time employees and an increase of $0.6 million in stock based compensation expense due to new stock options and restricted stock units granted to research and development full-time employees.
General and Administrative Expenses
General and administrative expenses were $8.9 million for the nine months ended September 30, 2022, compared to $8.0 million for the nine months ended September 30, 2021. The increase of $0.9 million in general and administrative expenses was primarily due to an increase of a $0.4 million in stock based compensation expense due to new stock options and restricted stock units granted to general and administrative full-time employees and an increase of $0.3 million in payroll and other related expenses due to an increase in headcount of our general and administrative full-time employees and an increase in compensation expense. There was also an increase of $0.2 million in professional fees due to higher recruiting costs.
Interest Income
During the nine months ended September 30, 2022, we recorded interest income of $0.4 million. During the nine months ended September 30, 2021, we recorded an immaterial amount of interest income. The increase of $0.4 million during the nine months ended September 30, 2022 as compared to the same period in 2021 was due to higher interest rates.
Australian Research and Development Incentives
We recorded R&D incentive income of $1.3 million and $1.6 million, respectively, during the nine months ended September 30, 2022 and 2021, based upon the applicable percentage of eligible research and development activities under the Australian Incentive Program, which expenses included the cost of manufacturing clinical trial material.
The R&D incentive receivable has been recorded as “Research and development incentive receivable” in the condensed consolidated balance sheets.
Foreign Currency Gains (loss)
During the nine months ended September 30, 2022 and 2021, we recorded foreign currency losses of $1.3 million and $0.4 million, respectively. Foreign currency gains and losses are due to changes in the Australian dollar exchange rate related to activities of the Australian entity.
Financial Position, Liquidity and Capital Resources
Since our inception, we have been engaged in organizational activities, including raising capital, and research and development activities. We do not yet have a product that has been approved by the Food and Drug Administration (the “FDA”), have not yet achieved profitable operations, nor have we ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. Further, our future operations are dependent on the success of efforts to raise additional capital, our research and commercialization efforts, regulatory approval, and, ultimately, the market acceptance of our products.
In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. As of September 30, 2022, we had cash and cash equivalents of $78.3 million. Additionally, we had an accumulated deficit of $306.1 million at September 30, 2022, and during the nine months ended September 30, 2022, we incurred a net loss of $42.5 million. We expect to continue to generate operating losses in the foreseeable future. We believe that our cash and cash equivalents of $78.3 million as of September 30, 2022 will be sufficient to fund our operating expenses for at least the next 12 months from the filing of this report on Form 10-Q.
In addition, we will seek additional funding through public or private equity financings or government programs and will seek funding or development program cost-sharing through collaboration agreements or licenses with larger pharmaceutical or biotechnology companies. If we do not obtain additional funding or development program cost-sharing, we will be forced to delay, reduce or eliminate certain clinical trials or research and development programs, reduce or eliminate discretionary operating expenses, and delay company and pipeline expansion, which would adversely affect our business prospects. The inability to obtain funding, as and when needed, would have a negative impact on our financial condition and ability to pursue our business strategies.
Cash Flows
The following table summarizes our sources and uses of cash for each of the periods presented:
(in thousands)
| | | Nine Months Ended September 30, 2022 | | 2021 |
|---|---|---|---|---|
| Cash used in operating activities | | $(36,030) | | $(24,441) |
| Cash provided by (used in) financing activities | | (210) | | 97,280 |
| Effect of exchange rate changes on cash and cash equivalents | | (368) | | (139) |
| Net increase (decrease) in cash and cash equivalents | | $(36,608) | | $72,700 |
Operating activities. Net cash used in operating activities for the nine months ended September 30, 2022 was primarily related to our net loss from the operation of our business of $42.5 million and net changes in working capital, including an increase in other long term assets of $0.9 million, a decrease in lease liability of $0.3 million and an increase in research and development receivable of $0.2 million. These changes were partially offset by an increase in accounts payable and accrued expenses of $2.2 million and a decrease of $0.4 million in prepaid expenses. During the nine months ended September 30, 2022, there was also noncash stock based compensation expense of $3.7 million, foreign currency losses of $1.3 million and a change in right-of-use asset of $0.3 million.
Net cash used in operating activities for the nine months ended September 30, 2021 was primarily related to our net loss from the operation of our business of $29.8 million and net changes in working capital, including an increase of $1.6 million in research and development incentive receivable, a decrease of $1.1 million in deferred revenue, an increase of $0.1 million in prepaid expenses and other assets, a decrease in lease liabilities of $0.2 million and a $0.2 million decrease related to change in restricted stock liability. These changes were partially offset by an increase in accounts payable and accrued expenses of $4.9 million, a decrease in deferred offering costs of $0.2 million, foreign currency losses of $0.4 million, noncash stock based compensation expense of $2.7 million, change in a right-of-use asset of $0.2 million and amortization of contract asset of $0.1 million.
Investing Activities. There were no investing activities during the nine months ended September 30, 2022 and 2021.
Financing Activities. Net cash used in financing activities for the nine months ended September 30, 2022 consisted of payments of deferred offering costs of $0.2 million. Net cash provided by financing activities for the nine months ended September 30, 2021 consisted of $97.2 million in net proceeds from the issuance of common stock in connection with the public offering the Company completed in September 2021 (the “2021 Public Offering”) and $0.1 million in proceeds from the issuance of common stock upon the exercise of stock options and warrants.
Controls and procedures
As filed, 2,492 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our President and Chief Executive Officer, who is also serving as Chief Financial Officer and therefore currently serves as both our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
As of September 30, 2022, our management, with the participation of our Chief Executive Officer, who is also serving as Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated Framework (2013 Framework). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer has concluded, based upon the evaluation described above, that, as of September 30, 2022, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such material information is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
During the nine months ended September 30, 2022, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that materially affected, or are reasonably likely to affect, internal control over financial reporting.
Risk factors
As filed, 2,267 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
An investment in our ordinary shares involves a high degree of risk. You should carefully consider the risk factors discussed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 11, 2022, which could materially affect our business, financial condition, operating results or cash flows. The information presented below updates, and should be read in conjunction with, the risk factors and information disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 11, 2022. Except as presented below, there have been no material changes from the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2021.
We are not in compliance with the Nasdaq continued listing requirements. If we are unable to comply with the continued listing requirements of the Nasdaq Global Market, our common stock could be delisted, which could affect our common stock's market price and liquidity and reduce our ability to raise capital.
On November 2, 2022, we received a letter (the “Notice”) from the Nasdaq Stock Market, or Nasdaq, notifying us that, because the closing bid price for our common stock, par value $0.001 per share (the “Common Stock”), has been below $1.00 per share for the past 30 consecutive business days, it no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Market. The Notice has no immediate effect on our listing on the Nasdaq Global Market or on the trading of the Common Stock. The Notice provides us with a compliance period of 180 calendar days, or until May 1, 2023, to regain compliance. If at any time during this 180-day compliance period the closing bid price of the Common Stock is at least $1.00 per share for a minimum of 10 consecutive business days, then Nasdaq will provide us with written confirmation of compliance and the matter will be closed. We intend to monitor the closing bid price of the Common Stock and may, if appropriate, evaluate various courses of action to regain compliance. There can be no assurance that we will regain compliance or otherwise maintain compliance with the other listing requirements.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2022-07-01 to 2022-09-30 | $12.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-01-01 to 2022-09-30 | $33.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | −$15.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | −$42.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-07-01 to 2022-09-30 | $11.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2022-01-01 to 2022-09-30 | $49.0k | us-gaap:InterestExpense |
| Net income | 3 months2022-07-01 to 2022-09-30 | −$15.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | −$42.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | −$0.13 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | −$0.38 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | −$0.13 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | −$0.38 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 113,239,092 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 113,239,092 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | −$36.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2022-09-30 | $78.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $79.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $82.2m | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $11.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $12.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-09-30 | $70.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-22-117613. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.